Clovis Oncology (NASDAQ:CLVS) : Average target price received by Clovis Oncology (NASDAQ:CLVS) is $19.5 with an expected standard deviation of $6.16. The most aggressive target on the stock is $30, whereas the most downbeat target is $14. 6 financial analysts are currently covering the stock.
Clovis Oncology, Inc. has lost 1.51% in the last five trading days and dropped 19.53% in the last 4 weeks. Clovis Oncology, Inc. has dropped 29.17% during the last 3-month period . Year-to-Date the stock performance stands at -60.8%. Also, In the latest statement by the brokerage house, JP Morgan downgrades its outlook on Clovis Oncology (NASDAQ:CLVS). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Overweight. The brokerage firm lowers the price target from $42 per share to $15 per share. The rating by the firm was issued on April 13, 2016.
Clovis Oncology (NASDAQ:CLVS) : The consensus on Clovis Oncology (NASDAQ:CLVS) based on 6 analyst recommendation on the company stock is 2.33, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Clovis Oncology (NASDAQ:CLVS): The stock opened at $14.64 on Thursday but the bulls could not build on the opening and the stock topped out at $14.88 for the day. The stock traded down to $13.10 during the day, due to lack of any buying support eventually closed down at $13.72 with a loss of -8.90% for the day. The stock had closed at $15.06 on the previous day. The total traded volume was 3,729,397 shares.
In an insider trading activity,The officer (Executive VP and CFO) of Clovis Oncology, Inc., Mast Erle T sold 3,000 shares at $104.18 on November 2, 2015. The Insider selling transaction had a total value worth of $312,540. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.